<p><strong>融資包括醫療專注投資者與現有股東的參與</strong></p>
<p>多倫多，2025 年 12 月 19 日（GLOBE NEWSWIRE）-- <strong>Profound Medical Corp.（納斯達克：PROF；多倫多證券交易所：PRN）</strong>（“Profound” 或 “公司”）今天宣佈以每股 7.00 美元的價格出售 5,142,857 股普通股，進行註冊直接發行，並計劃在加拿大進行後續私人配售，最多 571,428 股普通股，購買價格為每股 7.00 美元，預計總收益可達 4000 萬美元。</p>
<p>此次註冊直接發行被結構化為一種簡單的股權投資，沒有認股權證覆蓋，由醫療專注投資者與現有股東共同主導。該部分發行預計將在 2025 年 12 月 22 日（星期一）左右完成，具體取決於滿足慣常的交割條件。</p>
<p>公司預計此次發行的總收益約為 3600 萬美元，未扣除配售代理費用和公司需支付的其他發行費用。公司打算將發行的淨收益用於銷售和市場擴展、營運資金、研發、戰略交易和一般公司用途。</p>
<p><strong>Konik Capital Partners, LLC，T.R. Winston and Company, LLC 的一個部門，作為此次發行的獨家配售代理。</strong></p>
<p>此次發行是根據已生效的 S-3 表格（文件編號 333-291516）進行的，該表格已於 2025 年 12 月 4 日向證券交易委員會（“SEC”）提交併獲得批准。此次發行僅通過補充招股説明書和附帶的基礎招股説明書進行，這些文件構成有效的架構註冊聲明的一部分。與此次發行相關的補充招股説明書和附帶的基礎招股説明書將提交給 SEC，並可在 SEC 網站 http://www.sec.gov 上獲取。此外，當可用時，補充招股説明書和附帶的基礎招股説明書的電子副本可從 Konik Capital Partners 獲取，地址為紐約，世界貿易中心 7 號，46 層，或通過電子郵件聯繫 capmarkets@konikcapitalpartners.com。</p>
<p>本新聞稿不構成出售或招攬購買本文所述證券的要約，也不應在任何州或其他司法管轄區進行這些證券的銷售，除非在該州或其他司法管轄區的證券法下進行註冊或資格認證。</p>
<p>除了註冊直接發行外，公司還打算完成一項私人配售（“私人配售”），最多 571,428 股普通股，購買價格為每股 7.00 美元，預計總收益可達 400 萬美元，面向某些加拿大買家進行私人配售。根據私人配售出售的普通股將受到四個月加一天的持有期限制，從私人配售的交割日期起算。私人配售的交割預計將在 2025 年 12 月 30 日之前進行，具體取決於公司獲得所有必要的批准，包括多倫多證券交易所的有條件批准。私人配售下不會向美國買家出售任何證券，本新聞稿不構成在美國或任何其他司法管轄區出售或招攬購買此類證券的要約，除非在該司法管轄區的證券法下進行資格認證或註冊。私人配售下所提供的證券尚未，也不會根據美國證券法進行註冊，且在未註冊或適用的美國註冊要求和適用的美國州證券法的豁免情況下，這些證券不得在美國境內或向美國人士提供或出售。</p>
<p><strong>關於 Profound Medical Corp.</strong></p>
<p>Profound 是一家商業階段的醫療設備公司，開發和銷售基於人工智能的、MRI 引導的、無切口的疾病組織消融療法。</p>
<p>Profound 正在商業化 TULSA-PRO®，這是一項結合實時 MRI、AI 增強規劃、機器人驅動的經尿道超聲和閉環温度反饋控制的技術。TULSA 程序™，使用 TULSA-PRO 系統進行，具有成為整個前列腺疾病譜系主流治療方式的潛力；涵蓋低、中、高風險前列腺癌；同時適用於同時患有前列腺癌和良性前列腺增生（“BPH”）的混合患者；僅患有 BPH 的男性；以及需要針對放射覆發局部前列腺癌進行挽救治療的患者。TULSA 程序採用實時 MRI 引導，以精確保護患者的尿失禁和性功能，同時通過精確的聲吸收技術將目標前列腺組織加熱至 55-57°C。TULSA 是一種無切口、無輻射的 “一次性” 程序，在一個會話中完成，持續幾個小時。幾乎所有形狀和大小的前列腺都可以安全、有效和高效地使用 TULSA 進行治療。該程序沒有出血；不需要住院；大多數 TULSA 患者報告迅速恢復到正常生活。TULSA-PRO 已獲得 CE 標誌、加拿大衞生部批准，並獲得美國食品藥品監督管理局（“FDA”）的 510(k) 清關。</p>
<p>Profound 還在商業化 Sonalleve®，這是一種創新的治療平台，已獲得 CE 認證，用於治療子宮肌瘤、子宮腺肌症、骨轉移疼痛緩解、纖維瘤和骨樣骨瘤。Sonalleve 還獲得了中國國家藥品監督管理局的批准，用於非侵入性治療子宮肌瘤，並在美國獲得了人道主義設備豁免下的 FDA 批准，用於治療骨樣骨瘤。Profound 正在早期階段探索 Sonalleve 的其他潛在治療市場，該技術已顯示出臨牀應用，例如非侵入性消融腹部癌症和癌症治療的高温療法。</p>
<p><strong>前瞻性聲明</strong></p>
<p>本公告包含關於 Profound 及其業務的前瞻性聲明，這些聲明可能包括但不限於與公司預期收益使用、預計現金流和發行結束相關的聲明。通常，但並不總是，前瞻性聲明可以通過使用 “計劃”、“預計”、“期望”、“安排”、“打算”、“考慮”、“預期”、“相信”、“提議” 或這些詞語和短語的變體（包括否定變體）來識別，或聲明某些行動、事件或結果 “可能”、“可以”、“將”、“可能” 或 “會” 被採取、發生或實現。這些聲明基於 Profound 管理層的當前預期。本公告中討論的前瞻性事件和情況，可能不會在某些特定日期或根本不發生，並可能因影響公司的已知和未知風險因素和不確定性而有實質性差異，包括計劃的私募配售。儘管 Profound 已嘗試識別可能導致實際行動、事件或結果與前瞻性聲明中描述的內容有實質性差異的重要因素，但可能還有其他因素導致行動、事件或結果與預期、估計或意圖的內容不同。沒有任何前瞻性聲明可以得到保證。可能導致實際結果與前瞻性聲明中所列內容有實質性差異的其他因素和風險在 Profound 的 10-K 表格年度報告及其他向美國和加拿大證券監管機構提交的文件中進行了描述，相關文件可在 www.sedarplus.ca 和 www.sec.gov 獲取。除非適用的證券法要求，前瞻性聲明僅在作出時有效，Profound 不承擔公開更新或修訂任何前瞻性聲明的義務，無論是由於新信息、未來事件還是其他原因，除非法律要求。</p>
<p><strong>如需更多信息，請聯繫：</strong></p>
<p>Stephen Kilmer</p>
<p>投資者關係</p>
<p>skilmer@profoundmedical.com</p>
<p>電話：647.872.4849</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZd05URXpOaU0zTXpNd05UYzRJekl3TVRnMU5EYz0?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZd05URXpOaU0zTXpNd05UYzRJekl3TVRnMU5EYz0"/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/MGUyZmJhMzgtZDg2NS00NzU0LTk5ZDAtZTEyMjZlYjI4ZmY1LTEwMzAxMTktMjAyNS0xMi0xOS1lbg==/tiny/Profound-Medical-Inc-.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/MGUyZmJhMzgtZDg2NS00NzU0LTk5ZDAtZTEyMjZlYjI4ZmY1LTEwMzAxMTktMjAyNS0xMi0xOS1lbg==/tiny/Profound-Medical-Inc-.png"/></p>

PROF

<p>Profound Medical Corp. 宣佈進行 4000 萬美元的融資，其中包括 3600 萬美元的註冊直接發行和 400 萬美元的私募。此次發行涉及醫療保健投資者和現有股東，所得款項將用於銷售擴展、研發和公司用途。直接發行預計將在 2025 年 12 月 22 日完成，私募預計在 2025 年 12 月 30 日完成，需獲得相關批准。該公司開發基於人工智能的 MRI 引導療法用於前列腺疾病治療</p>

<p><strong>Financing included participation by healthcare-dedicated investors alongside existing shareholders</strong></p>
<div class="lb-trans"><p><strong>融資包括醫療專注投資者與現有股東的參與</strong></p>
</div><p>TORONTO, Dec. 19, 2025 (GLOBE NEWSWIRE) -- <strong>Profound Medical Corp. (Nasdaq:PROF; TSX:PRN)</strong> (“Profound” or the “Company”) today announced the sale of 5,142,857 common shares at a purchase price of $7.00 per share in a registered direct offering and a planned subsequent private placement in Canada of up to 571,428 common shares at a purchase price of $7.00 per share for aggregate gross proceeds of up to $40 million.</p>
<div class="lb-trans"><p>多倫多，2025 年 12 月 19 日（GLOBE NEWSWIRE）-- <strong>Profound Medical Corp.（納斯達克：PROF；多倫多證券交易所：PRN）</strong>（“Profound” 或 “公司”）今天宣佈以每股 7.00 美元的價格出售 5,142,857 股普通股，進行註冊直接發行，並計劃在加拿大進行後續私人配售，最多 571,428 股普通股，購買價格為每股 7.00 美元，預計總收益可達 4000 萬美元。</p>
</div><p>The registered direct offering was structured as a straightforward equity investment with no warrant coverage and was led by healthcare-dedicated investors alongside existing shareholders. This portion of the offering is expected to close on or about Monday, December 22, 2025, subject to the satisfaction of customary closing conditions.</p>
<div class="lb-trans"><p>此次註冊直接發行被結構化為一種簡單的股權投資，沒有認股權證覆蓋，由醫療專注投資者與現有股東共同主導。該部分發行預計將在 2025 年 12 月 22 日（星期一）左右完成，具體取決於滿足慣常的交割條件。</p>
</div><p>Gross proceeds to the Company from the offering are expected to be approximately $36 million, before deducting placement agent’s fees and other offering expenses payable by the Company. The Company intends to use the net proceeds from the offering for expansion of its sales and marketing, working capital, research and development, strategic transactions and general corporate purposes.</p>
<div class="lb-trans"><p>公司預計此次發行的總收益約為 3600 萬美元，未扣除配售代理費用和公司需支付的其他發行費用。公司打算將發行的淨收益用於銷售和市場擴展、營運資金、研發、戰略交易和一般公司用途。</p>
</div><p><strong>Konik Capital Partners, LLC, a division of T.R. Winston and Company, LLC, is acting as the exclusive placement agent for this offering.</strong></p>
<div class="lb-trans"><p><strong>Konik Capital Partners, LLC，T.R. Winston and Company, LLC 的一個部門，作為此次發行的獨家配售代理。</strong></p>
</div><p>This offering is being made pursuant to an effective shelf registration statement on Form S-3 (File No. 333-291516) which was previously filed with and declared effective by the Securities and Exchange Commission (the “SEC”) on December 4, 2025. The offering is being made only by means of a prospectus supplement and accompanying base prospectus which form a part of the effective shelf registration statement. A prospectus supplement and the accompanying base prospectus relating to the offering will be filed with the SEC and will be available on the SEC’s website located at http://www.sec.gov. Additionally, when available, electronic copies of the prospectus supplement and the accompanying base prospectus may be obtained, when available, from Konik Capital Partners, 7 World Trade Center, 46th Floor, New York, NY, or by email at capmarkets@konikcapitalpartners.com.</p>
<div class="lb-trans"><p>此次發行是根據已生效的 S-3 表格（文件編號 333-291516）進行的，該表格已於 2025 年 12 月 4 日向證券交易委員會（“SEC”）提交併獲得批准。此次發行僅通過補充招股説明書和附帶的基礎招股説明書進行，這些文件構成有效的架構註冊聲明的一部分。與此次發行相關的補充招股説明書和附帶的基礎招股説明書將提交給 SEC，並可在 SEC 網站 http://www.sec.gov 上獲取。此外，當可用時，補充招股説明書和附帶的基礎招股説明書的電子副本可從 Konik Capital Partners 獲取，地址為紐約，世界貿易中心 7 號，46 層，或通過電子郵件聯繫 capmarkets@konikcapitalpartners.com。</p>
</div><p>This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation, or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.</p>
<div class="lb-trans"><p>本新聞稿不構成出售或招攬購買本文所述證券的要約，也不應在任何州或其他司法管轄區進行這些證券的銷售，除非在該州或其他司法管轄區的證券法下進行註冊或資格認證。</p>
</div><p>In addition to the registered direct offering, the Company intends to complete a private placement (the “Private Placement”) of up to 571,428 common shares at a purchase price of $7.00 per share, for aggregate gross proceeds of up to $4 million, to certain Canadian purchasers on a private placement basis. The common shares sold pursuant to the Private Placement will be subject to a hold period of four months plus one day from the closing date of the Private Placement. The closing of the Private Placement is expected to occur on or prior to December 30, 2025 and is subject to the Company receiving all necessary approvals, including the conditional approval from the Toronto Stock Exchange. No securities will be sold under the Private Placement to United States purchasers and this press release is not an offer to sell or the solicitation of an offer to buy such securities in the United States or in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to qualification or registration under the securities laws of such jurisdiction. The securities being offered under the Private Placement have not been, nor will they be, registered under the U.S. Securities Act, and such securities may not be offered or sold within the United States or to, or for the account or benefit of, U.S. persons absent registration or an applicable exemption from U.S. registration requirements and applicable U.S. state securities laws.</p>
<div class="lb-trans"><p>除了註冊直接發行外，公司還打算完成一項私人配售（“私人配售”），最多 571,428 股普通股，購買價格為每股 7.00 美元，預計總收益可達 400 萬美元，面向某些加拿大買家進行私人配售。根據私人配售出售的普通股將受到四個月加一天的持有期限制，從私人配售的交割日期起算。私人配售的交割預計將在 2025 年 12 月 30 日之前進行，具體取決於公司獲得所有必要的批准，包括多倫多證券交易所的有條件批准。私人配售下不會向美國買家出售任何證券，本新聞稿不構成在美國或任何其他司法管轄區出售或招攬購買此類證券的要約，除非在該司法管轄區的證券法下進行資格認證或註冊。私人配售下所提供的證券尚未，也不會根據美國證券法進行註冊，且在未註冊或適用的美國註冊要求和適用的美國州證券法的豁免情況下，這些證券不得在美國境內或向美國人士提供或出售。</p>
</div><p><strong>About Profound Medical Corp.</strong></p>
<div class="lb-trans"><p><strong>關於 Profound Medical Corp.</strong></p>
</div><p>Profound is a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue.</p>
<div class="lb-trans"><p>Profound 是一家商業階段的醫療設備公司，開發和銷售基於人工智能的、MRI 引導的、無切口的疾病組織消融療法。</p>
</div><p>Profound is commercializing TULSA-PRO®, a technology that combines real-time MRI, AI-enhanced planning, robotically-driven transurethral ultrasound and closed-loop temperature feedback control. The TULSA Procedure™, performed using the TULSA-PRO system, has the potential of becoming a mainstream treatment modality across the entire prostate disease spectrum; ranging from low-, intermediate-, or high-risk prostate cancer; to hybrid patients suffering from both prostate cancer and benign prostatic hyperplasia (“BPH”); to men with BPH only; and also, to patients requiring salvage therapy for radio-recurrent localized prostate cancer. The TULSA Procedure employs real-time MR guidance for precision to preserve patients’ urinary continence and sexual function, while killing the targeted prostate tissue via precise sound absorption technology that gently heats it to 55-57°C. TULSA is an incision- and radiation-free “one-and-done” procedure performed in a single session that takes a few hours. Virtually all prostate shapes and sizes can be safely, effectively, and efficiently treated with TULSA. There is no bleeding associated with the procedure; no hospital stay is required; and most TULSA patients report quick recovery to their normal routine. TULSA-PRO is CE marked, Health Canada approved, and 510(k) cleared by the U.S. Food and Drug Administration (“FDA”).</p>
<div class="lb-trans"><p>Profound 正在商業化 TULSA-PRO®，這是一項結合實時 MRI、AI 增強規劃、機器人驅動的經尿道超聲和閉環温度反饋控制的技術。TULSA 程序™，使用 TULSA-PRO 系統進行，具有成為整個前列腺疾病譜系主流治療方式的潛力；涵蓋低、中、高風險前列腺癌；同時適用於同時患有前列腺癌和良性前列腺增生（“BPH”）的混合患者；僅患有 BPH 的男性；以及需要針對放射覆發局部前列腺癌進行挽救治療的患者。TULSA 程序採用實時 MRI 引導，以精確保護患者的尿失禁和性功能，同時通過精確的聲吸收技術將目標前列腺組織加熱至 55-57°C。TULSA 是一種無切口、無輻射的 “一次性” 程序，在一個會話中完成，持續幾個小時。幾乎所有形狀和大小的前列腺都可以安全、有效和高效地使用 TULSA 進行治療。該程序沒有出血；不需要住院；大多數 TULSA 患者報告迅速恢復到正常生活。TULSA-PRO 已獲得 CE 標誌、加拿大衞生部批准，並獲得美國食品藥品監督管理局（“FDA”）的 510(k) 清關。</p>
</div><p>Profound is also commercializing Sonalleve®, an innovative therapeutic platform that is CE marked for the treatment of uterine fibroids, adenomyosis, pain palliation of bone metastases, desmoid tumors and osteoid osteoma. Sonalleve has also been approved by the China National Medical Products Administration for the non-invasive treatment of uterine fibroids and has FDA approval under a Humanitarian Device Exemption for the treatment of osteoid osteoma. Profound is in the early stages of exploring additional potential treatment markets for Sonalleve where the technology has been shown to have clinical application, such as non-invasive ablation of abdominal cancers and hyperthermia for cancer therapy.</p>
<div class="lb-trans"><p>Profound 還在商業化 Sonalleve®，這是一種創新的治療平台，已獲得 CE 認證，用於治療子宮肌瘤、子宮腺肌症、骨轉移疼痛緩解、纖維瘤和骨樣骨瘤。Sonalleve 還獲得了中國國家藥品監督管理局的批准，用於非侵入性治療子宮肌瘤，並在美國獲得了人道主義設備豁免下的 FDA 批准，用於治療骨樣骨瘤。Profound 正在早期階段探索 Sonalleve 的其他潛在治療市場，該技術已顯示出臨牀應用，例如非侵入性消融腹部癌症和癌症治療的高温療法。</p>
</div><p><strong>Forward-Looking Statements</strong></p>
<div class="lb-trans"><p><strong>前瞻性聲明</strong></p>
</div><p>This release includes forward-looking statements regarding Profound and its business which may include, but is not limited to, statements relating to the Company’s anticipated use of proceeds, expected cash runway and the closing of the offering. Often, but not always, forward-looking statements can be identified by the use of words such as “plans”, “is expected”, “expects”, “scheduled”, “intends”, “contemplates”, “anticipates”, “believes”, “proposes” or variations (including negative variations) of such words and phrases, or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. Such statements are based on the current expectations of the management of Profound. The forward-looking events and circumstances discussed in this release, may not occur by certain specified dates or at all and could differ materially as a result of known and unknown risk factors and uncertainties affecting the Company, including the planned Private Placement. Although Profound has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended. No forward-looking statement can be guaranteed. Other factors and risks that may cause actual results to differ materially from those set out in the forward-looking statements are described in Profound’s Annual Report on Form 10-K and other filings made with U.S. and Canadian securities regulators, available at www.sedarplus.ca and www.sec.gov. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and Profound undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise, other than as required by law.</p>
<div class="lb-trans"><p>本公告包含關於 Profound 及其業務的前瞻性聲明，這些聲明可能包括但不限於與公司預期收益使用、預計現金流和發行結束相關的聲明。通常，但並不總是，前瞻性聲明可以通過使用 “計劃”、“預計”、“期望”、“安排”、“打算”、“考慮”、“預期”、“相信”、“提議” 或這些詞語和短語的變體（包括否定變體）來識別，或聲明某些行動、事件或結果 “可能”、“可以”、“將”、“可能” 或 “會” 被採取、發生或實現。這些聲明基於 Profound 管理層的當前預期。本公告中討論的前瞻性事件和情況，可能不會在某些特定日期或根本不發生，並可能因影響公司的已知和未知風險因素和不確定性而有實質性差異，包括計劃的私募配售。儘管 Profound 已嘗試識別可能導致實際行動、事件或結果與前瞻性聲明中描述的內容有實質性差異的重要因素，但可能還有其他因素導致行動、事件或結果與預期、估計或意圖的內容不同。沒有任何前瞻性聲明可以得到保證。可能導致實際結果與前瞻性聲明中所列內容有實質性差異的其他因素和風險在 Profound 的 10-K 表格年度報告及其他向美國和加拿大證券監管機構提交的文件中進行了描述，相關文件可在 www.sedarplus.ca 和 www.sec.gov 獲取。除非適用的證券法要求，前瞻性聲明僅在作出時有效，Profound 不承擔公開更新或修訂任何前瞻性聲明的義務，無論是由於新信息、未來事件還是其他原因，除非法律要求。</p>
</div><p><strong>For further information, please contact:</strong></p>
<div class="lb-trans"><p><strong>如需更多信息，請聯繫：</strong></p>
</div><p>Stephen Kilmer</p>
<div class="lb-trans"><p>Stephen Kilmer</p>
</div><p>Investor Relations</p>
<div class="lb-trans"><p>投資者關係</p>
</div><p>skilmer@profoundmedical.com</p>
<div class="lb-trans"><p>skilmer@profoundmedical.com</p>
</div><p>T: 647.872.4849</p>
<div class="lb-trans"><p>電話：647.872.4849</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZd05URXpOaU0zTXpNd05UYzRJekl3TVRnMU5EYz0" alt="" original-src="https://www.globenewswire.com/newsroom/ti?nf=OTYwNTEzNiM3MzMwNTc4IzIwMTg1NDc="/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/MGUyZmJhMzgtZDg2NS00NzU0LTk5ZDAtZTEyMjZlYjI4ZmY1LTEwMzAxMTktMjAyNS0xMi0xOS1lbg==/tiny/Profound-Medical-Inc-.png" alt="" original-src="https://ml.globenewswire.com/media/MGUyZmJhMzgtZDg2NS00NzU0LTk5ZDAtZTEyMjZlYjI4ZmY1LTEwMzAxMTktMjAyNS0xMi0xOS1lbg==/tiny/Profound-Medical-Inc-.png"/></p>

Profound Medical Corp. Announces Pricing of up to $40 Million Financing Comprised of a $36 Million Registered Direct Offering and a Subsequent $4 Million Private Placement | PROF Stock News

Profound Medical Corp.宣佈定價高達 4000 萬美元的融資計劃，其中包括 3600 萬美元的註冊直接發行和隨後 400 萬美元的私人配售 | PROF 股票新聞